Hospital Clinic Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (3)

2015

  1. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial

    JAMA Oncology, Vol. 1, Núm. 2, pp. 149-157

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246

2006

  1. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial

    Annals of Oncology, Vol. 17, Núm. 3, pp. 467-472